April -
- Net sales:
SEK 9.1 million (11.2) -
Operating income:
SEK -3.9 million (-1.7) -
Net income for the period:
SEK -3.9 million (-1.7) -
Earnings per share:
SEK -0.05 (-0.02)
Summary of the quarter
- Decreased sales by 19% despite the second best second quarter in ten years.
-
The first blood group incompatible kidney transplants with Glycosorb® ABO are performed in
Hong Kong andBelgium . - Training and start-up of our technology in six new transplant centers.
- Glycorex participates in three international transplantation congresses.
- Glycorex participates for the first time in an international transfusion congress.
-
The method for performing blood group-incompatible heart transplants in children using Glycosorb® ABO is presented by Dr
Richard Issitt fromGreat Ormond Street Hospital inEngland at two American congresses. -
Of all organ transplants performed with Glycosorb® ABO in
India , over 22 per cent were liver transplants from living donors.
CEO comment
"During the second quarter of the year, sales amounted to
The quarter was characterized by a high level of activity with many customer interactions, participation in international congresses and training and start-up of our technology in new transplant centers. After the end of the quarter, we also strengthened our organization in the Transfusion business area through the recruitment of a dedicated Business Development Manager.
Glycorex's ambition is to establish sustainable and profitable growth. Our resources are limited and must be focused on the areas where they have the greatest effect. During the autumn, we will therefore review our expenses to ensure that every krona is invested in areas that can drive growth whilst continuing to develop the company's commercial and sales-oriented part in line with the previously communicated growth strategy.
Let me conclude by saying that after nine months as CEO of Glycorex, I am strengthened in my conviction that our strategy together with increased focus and efficiency will lead to a strong development in the coming years. It is hugely motivating to know that our hard work and unique technology ultimately contribute to saving lives and improving the quality of life of many critically ill patients."
- Johan Lavén, CEO
For more information, please contact:
Johan Lavén, CEO
Email: johan.laven@glycorex.com
Tel: + 46 (0)73 330 92 16
This information is the kind of information
Brief information about the company
Glycosorb® ABO is one of the company's self-developed proprietary medical devices that is used to facilitate blood group-incompatible transplants. Whilst primarily used to facilitate blood group incompatible kidney transplants, Glycosorb® ABO is also used in blood group incompatible liver-, heart-, lung-, and stem cell transplants. More than 60 scientific papers have been published in reputable medical journals, showing excellent short- and long-term outcomes of blood group incompatible transplants performed with Glycosorb® ABO. Glycosorb® ABO has been used in more than 6,000 transplants in over 25 countries. In addition to
The company has also developed a CE-marked medical device product for the production of universal (low titer) blood products and is collaborating with a leading European research institute to develop a product for the treatment of the autoimmune disease rheumatoid arthritis.
https://news.cision.com/glycorex-transplantation/r/glycorex-transplantation-ab--publ--interim-report-january---june-2023,c3825977
https://mb.cision.com/Main/15286/3825977/2261013.pdf
https://mb.cision.com/Public/15286/3825977/850f14465a03660d.pdf
(c) 2023 Cision. All rights reserved., source